Abstract: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal.

Abstract: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal.

Abstract: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal.

Abstract: The present invention is directed to methods for delivering cells to a target tissue in a mammal using glycoconjugate to traffic the cell to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal.

Abstract: A device and method for inactivating pathogens in therapeutic fluids with sterilizing radiation in a continuous thin fluid flow arrangement that exhibits radiation dose uniformity for fluids having high optical densities. Radiation dose uniformity is achieved in part through a “carrying” mechanism that moves or carries the fluid, thereby eliminating a channel flow velocity profile where flow volumes near the channel walls run the risk of overexposure to the radiation due to very large residence times within the channel. The device comprises a relatively flat belt chamber (22) connected to a fluid flow through an inlet (24) and an outlet (26) on the belt chamber (22). The belt chamber (22) has a top surface (28) and a bottom surface (30). A radiation permeable plate (32) is disposed adjacent the top surface (28) of the belt chamber (22) and is in contact with the belt chamber (22). A radiation source (42) is provided adjacent to the plate (32) adjacent to a side opposite the belt chamber (22).

Abstract: A device and method for inactivating pathogens in therapeutic fluids with sterilizing radiation in a continuous flow arrangement while exhibiting radiation dose uniformity and narrow residence time distribution of the fluid within the device. The device (10) comprises a radiation permeable cylindrical tube (12) having a concentric cylindrical rotor (14) disposed therein, thereby providing a thin gap (16) therebetween. A top plate (18) having a fluid outlet (26) and a bottom plate (20) having a fluid inlet (24) seal the cylindrical tube (12). The inlet (24) and outlet (26) are both in fluid communication with the thin gap (16). A rotor shaft (36) is disposed axially through the cylindrical rotor (14) and is connected to a motor (30). A pump provides fluid flow through the device (10). A radiation source provides sterilizing radiation to the fluid through the cylindrical tube (12).

Abstract: A tyrosine-substituted hirudin analog has antithrombogenic activity. Further simultaneous reaction at native tyrosine residues is prevented by mutation at those sites to encode nonreactive amino acids. Several novel strategies for coupling the hirudin analog to solid surfaces while simultaneously conserving antithrombogenic activity are disclosed.